EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)

A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma

Minlin Jiang, Jiya Sun, Congli Hu, Lin Wu, Yun Fan, Zhehai Wang, Lianke Liu, Chunyan Wu, Fengying Wu, Guanghui Gao, Fei Li, Lei Wang und 5 weitere

Med · 2025

DOI: 10.1016/j.medj.2024.09.005 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Med, 2025. Verfasst von Minlin Jiang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine,…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Innovent Biologics Suzhou Co Ltd, Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Anti-PD-1 immunotherapy plus chemotherapy (combo) exhibits significantly prolonged survival for squamous cell lung cancer (LUSC). An exploration of predictive biomarkers is still needed. METHODS: High-throughput RNA sequencing (RNA-seq) of 349 LUSC samples from the randomized, multi-center, phase 3 trial ORIENT-12 (ClinicalTrials.gov: NCT03629925) was conducted for biomarker discovery, followed by flow cytometry and multiplex immunohistochemistry (mIHC) in additional clinical cohorts, and in vitro experiments were performed for verification. RESULTS: A high abundance of activated CD8+ T and CD56bright natural killer (NK) cells benefited patients' outcomes (progression-free survival [PFS]; overall survival [OS]) with combo treatment. Tumor cornification level remarkably affected the infiltration of the two crucial immune cells. Thus, a novel scheme of LUSC immune infiltration and cornification characterization-based classification (LICC) was established for combo efficacy prediction. Patients who received combo treatment achieved significant PFS improvements in LICC1 (hazard ratio [HR] = 0.43, 95% confidence interval [CI]: 0.25-0.75, p = 0.0029) and LICC2 (HR = 0.32, 95% CI: 0.17-0.58, p = 0.0002) subtypes but not in the LICC3 subtype (HR = 0.86, 95% CI: 0.60-1.23, p = 0.4053). Via single-cell RNA-seq analysis, the tumor cornification signal was mainly mapped to SPRR3+ tumor cells, whose relationships with activated CD8+ T or CD56bright NK cells were verified using flow cytometry and mIHC. Our data suggest that SPRR3+ tumor cells might evade immune surveillance via the CD24-SIGLEC10 (M2 macrophage) axis to maintain a suppressive tumor microenvironment. CONCLUSIONS: Tumor cornification greatly impacts immune infiltration, and the LICC scheme may guide clinical medication of anti-PD-1+chemo treatment in patients with LUSC. FUNDING: The study was funded by the National Key R&D Program of China, the National Natural Science Foundation of China, Shanghia Multidisplinary Cooperation Building Project for Diagnosis and Treatment of Major Disease, and Innovent Biologics, Inc.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellImmune Checkpoint InhibitorsLung NeoplasmsAgedFemaleHumansMaleMiddle AgedBiomarkers, TumorCD8-Positive T-LymphocytesKiller Cells, NaturalProgrammed Cell Death 1 ReceptorProgression-Free Survival

Stichwörter der Autor:innen

CD56(bright) NK cellsPD-1RNA-seqTranslation to patientsactivated CD8(+) T cellsbiomarkercornificationimmunotherapysingle-cell RNA-seqsquamous cell lung cancertumor microenvironment

Substanzen

Biomarkers, TumorImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, China; Medical School, Tongji University, Shanghai 2…
  • Innovent Biologics, Inc., Suzhou, Jiangsu 215123, China.
  • Thoracic Medicine Department II, Hunan Cancer Hospital, Changsha, Hunan 410031, China.
  • Oncology Department, Cancer Hospital of the University of Chinese Academy of Science, Hangzhou, Zhejiang 310005, China.
  • Respiratory Department, Shandong Cancer Hospital, Jinan, Shandong 250117, China.
  • Oncology Department, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China.

Förderung

  • National Natural Science Foundation of China
  • Innovent Biologics Suzhou Co Ltd
  • Shanghai Municipal Health Commission
  • National Key Research and Development Program of China

Zitieren

APA

Jiang, M., Sun, J., Hu, C., Wu, L., Fan, Y., Wang, Z., Liu, L., Wu, C., Wu, F., Gao, G., Li, F., Wang, L., Li, X., Cheng, L., Peng, B., Zhou, H., & Zhou, C. (2025). A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma. Med. https://doi.org/10.1016/j.medj.2024.09.005

Vancouver

Jiang M, Sun J, Hu C, Wu L, Fan Y, Wang Z, et al. A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma. Med. 2025. doi:10.1016/j.medj.2024.09.005

BibTeX
@article{Jiang2025,
  author = {Jiang, Minlin and Sun, Jiya and Hu, Congli and Wu, Lin and Fan, Yun and Wang, Zhehai and Liu, Lianke and Wu, Chunyan and Wu, Fengying and Gao, Guanghui and Li, Fei and Wang, Lei and Li, Xuefei and Cheng, Lei and Peng, Bo and Zhou, Hui and Zhou, Caicun},
  title = {A tumor cornification and immune-infiltration-based scheme for anti-PD-1 plus chemotherapy response in advanced squamous cell lung carcinoma},
  journal = {Med},
  year = {2025},
  doi = {10.1016/j.medj.2024.09.005}
}
Kostenlos starten →